Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review
- 111 Downloads
Tumor necrosis factor-α antagonists (anti-TNF-α) have been associated with drug-induced liver injury. However, cases of anti-TNF-α-associated acute liver failure have only been rarely reported.
To identify cases of anti-TNF-α-associated acute liver failure and evaluate patterns of liver injury and common characteristics to the cases.
The United States Acute Liver Failure Study Group database was searched from 1998 to 2014. Four subjects were identified. A PubMed search for articles that reported anti-TNF-α-associated acute liver failure identified five additional cases.
The majority of individuals affected were female (eight of nine cases). Age of individual ranged from 20 to 53 years. The most common anti-TNF-α agent associated with acute liver failure was infliximab (n = 8). The latency between initial drug exposure and acute liver failure ranged from 3 days to over a year. Of the nine cases, six required emergency LT. Liver biopsy was obtained in seven cases with a preponderance toward cholestatic–hepatitic features; none showed clear autoimmune features.
Anti-TNF-α-associated acute liver failure displays somewhat different characteristics compared with anti-TNF-α-induced drug-induced liver injury. Infliximab was implicated in the majority of cases. Cholestatic–hepatitic features were frequently found on pre-transplant and explant histology.
KeywordsDrug-induced liver injury Tumor necrosis factor-α antagonists Acute liver failure Liver transplant
Acute liver failure
Drug-induced liver injury
Herpes simplex virus
Human immunodeficiency virus
Intensive care unit
International normalized ratio
Roussel Uclaf Causality Assessment Method
- US ALFSG
United States Acute Liver Failure Study Group
Tumor necrosis factor-α
The study was sponsored by NIH Grant U-01 58369 (from NIDDK).
BK: Collected data and drafted individual case history, performed literature review and drafted the final manuscript. EL, WL, VP, JRP, CE: Collected data and drafted individual case histories and significantly revised final manuscript. SG: Reviewed case pathologies and significantly reviewed the final manuscript. WML: Reviewed all cases for causality and revised the final manuscript. AJH, RTS: Revised the final manuscript. CJK: Conceived the idea for the study, assisted in study design and case collection and significantly revised the final manuscript.
May be requested from the United States Acute Liver Failure Study Group at www.acuteliverfailure.org. Note: Two of the cases in this manuscript were described briefly in a published letter (Transplant Intl 2013 Dec; 26(12):e110-2.)
Compliance with ethical standards
Conflict of interest
- 2.FDA. Briefing document: Arthritis Advisory Committee., City. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm;2003
- 16.Tumor Necrosis Factor Antagonists. https://livertox.nlm.nih.gov//TumorNecrosisFactorAntagonists.htm
- 22.Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed February 2018
- 24.Chiu YM, Tang CH, Hung ST, Yang YW, Fang CH, Lin HY. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol. 2017;46:236–240.CrossRefPubMedGoogle Scholar